A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

The inaugural TCCI AI-Driven Science Symposium was held in San Francisco from Monday to Tuesday, bringing together three ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

Founded in 2018, Metagenomi is using a Nobel prize-winning approach developed by Jennifer Doudna and Emmanuelle Charpentier ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

It’s become a bit of a tradition for me to recap the Nobel Prizes in my column: In 2023, I covered Claudia Goldin’s work in ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...